Publication | Closed Access

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Surgical OncologyOncologyMelanomaImmunologyClinical TrialsImmune Checkpoint InhibitorImmunotherapyMedicineSkin Cancer